In October 2023, United Therapeutics acquired all of the outstanding equity of IVIVA Medical, Inc., a spin-out from the Harvard Stem Cell Institute addressing the chronic shortage of organs available for transplant. IVIVA is developing the IVIVA Kidney, a printed matrix cellularized with a patient’s own cells, which aids in the filtration and reabsorption functions of the native kidney.
Wilson Sonsini Goodrich & Rosati represented IVIVA in the transaction. The Wilson Sonsini team includes:
Corporate and Mergers & Acquisitions
Mark Solakian
Jake Gatof
Kristen D. Kercher
Priyanka W. Nawathe
Rozman Lynch
Eleanor Bleecker
Rebecca Lilley
Ryan Cooper
Technology Transactions
Seth Flaum
Jordin Wilcher
Stefan Geirhofer
Patents and Innovations
Christopher McAndrew
Employee Benefits and Compensation
Matthew C. Norgard
Jason Chan
Toni J. Hodge
FDA Regulatory
Georgia C. Ravitz
Paul S. Gadiock
Litigation
Matt Gorman
Quinn E. Christie
National Security
Kara D. Millard
Privacy and Cybersecurity
Matt Staples
Daniel Chen
Michael S. O'Brien
Diya Jajal